Publication: Therapy-Related Acute Myeloid Leukemia after CAR-T Cell Therapy with Brexucabtagene Autoleucel for Mantle Cell Lymphoma.
cris.virtual.author-orcid | 0000-0003-4474-3132 | |
cris.virtualsource.author-orcid | d3fcb446-375d-473f-afbb-fcb815a020d3 | |
cris.virtualsource.author-orcid | c441561b-2f62-41ef-8e09-fb335467e1b9 | |
cris.virtualsource.author-orcid | 62fb166c-c73f-4e79-b474-ba5d778eb98c | |
cris.virtualsource.author-orcid | d8f42926-f873-4a1f-839a-49eecd87333a | |
cris.virtualsource.author-orcid | 347baa39-8b2d-408d-922e-c504789f6476 | |
cris.virtualsource.author-orcid | 87c04196-fbb6-42b8-97bf-151846fee8ea | |
cris.virtualsource.author-orcid | 3ffc609d-4653-413a-a80f-2bf6c2b71f47 | |
cris.virtualsource.author-orcid | 1b65be99-ede2-4b0e-8e6d-1c720e453513 | |
datacite.rights | open.access | |
dc.contributor.author | Volery, François | |
dc.contributor.author | Banz, Yara | |
dc.contributor.author | Heini, Alexander | |
dc.contributor.author | Kronig, Marie-Noëlle | |
dc.contributor.author | Siegrist, Daniel | |
dc.contributor.author | Daskalakis, Michael | |
dc.contributor.author | Bacher, Ulrike | |
dc.contributor.author | Pabst, Thomas | |
dc.date.accessioned | 2024-11-08T09:42:31Z | |
dc.date.available | 2024-11-08T09:42:31Z | |
dc.date.issued | 2024 | |
dc.description.abstract | Introduction The introduction of CAR-T cell treatment for relapsed/refractory (r/r) mantle cell lymphoma improved survival rates of these patients. Along with its introduction in clinical routine, long-term events after CAR-T cell treatment are increasingly emerging.Case Presentation We report the case of a patient developing acute erythroid leukemia with biallelic TP53 inactivation occurring 26 months after CAR-T therapy with brexucabtagene autoleucel (brexu-cel) for r/r mantle cell lymphoma. The patient presented with a healthy bone marrow prior to lymphoma treatments.Discussion Secondary malignancies seem more frequent after CAR-T therapies. More studies are needed to assess potential long-term toxicities of CAR-T cell therapies including the frequency of secondary myeloid malignancies. | |
dc.description.sponsorship | Clinic of Medical Oncology | |
dc.description.sponsorship | Institute of Tissue Medicine and Pathology, Clinical Pathology | |
dc.description.sponsorship | Clinic of Haematology and Central Haematological Laboratory | |
dc.description.sponsorship | Department for BioMedical Research, Forschungsgruppe Hämatologie (Erwachsene) | |
dc.identifier.doi | 10.48620/76115 | |
dc.identifier.pmid | 39474550 | |
dc.identifier.publisherDOI | 10.1159/000541256 | |
dc.identifier.uri | https://boris-portal.unibe.ch/handle/20.500.12422/188820 | |
dc.language.iso | en | |
dc.publisher | Karger Publishers | |
dc.relation.ispartof | Case Reports in Oncology | |
dc.relation.issn | 1662-6575 | |
dc.subject | Acute erythroid leukemia | |
dc.subject | Acute myeloid leukemia | |
dc.subject | Brexucabtagene autoleucel | |
dc.subject | CAR-T | |
dc.subject | Mantle cell lymphoma | |
dc.title | Therapy-Related Acute Myeloid Leukemia after CAR-T Cell Therapy with Brexucabtagene Autoleucel for Mantle Cell Lymphoma. | |
dc.type | article | |
dspace.entity.type | Publication | |
dspace.file.type | text | |
oaire.citation.endPage | 1093 | |
oaire.citation.issue | 1 | |
oaire.citation.startPage | 1087 | |
oaire.citation.volume | 17 | |
oairecerif.author.affiliation | Clinic of Medical Oncology | |
oairecerif.author.affiliation | Institute of Tissue Medicine and Pathology, Clinical Pathology | |
oairecerif.author.affiliation | Clinic of Medical Oncology | |
oairecerif.author.affiliation | Clinic of Medical Oncology | |
oairecerif.author.affiliation | Clinic of Haematology and Central Haematological Laboratory | |
oairecerif.author.affiliation | Department for BioMedical Research, Forschungsgruppe Hämatologie (Erwachsene) | |
oairecerif.author.affiliation | Clinic of Haematology and Central Haematological Laboratory | |
oairecerif.author.affiliation | Clinic of Medical Oncology | |
oairecerif.author.affiliation2 | Institute of Tissue Medicine and Pathology | |
oairecerif.author.affiliation2 | Clinic of Haematology and Central Haematological Laboratory | |
oairecerif.author.affiliation2 | Department for BioMedical Research (DBMR) | |
unibe.contributor.role | author | |
unibe.contributor.role | author | |
unibe.contributor.role | author | |
unibe.contributor.role | author | |
unibe.contributor.role | author | |
unibe.contributor.role | author | |
unibe.contributor.role | author | |
unibe.contributor.role | corresponding author | |
unibe.description.ispublished | pub | |
unibe.refereed | true | |
unibe.subtype.article | contribution |
Files
Original bundle
1 - 1 of 1
- Name:
- 000541256.pdf
- Size:
- 1011.53 KB
- Format:
- Adobe Portable Document Format
- File Type:
- text
- License:
- https://creativecommons.org/licenses/by-nc/4.0
- Content:
- published